MX2018009820A - Uso de cart19 para eliminar celulas b normales para inducir tolerancia. - Google Patents

Uso de cart19 para eliminar celulas b normales para inducir tolerancia.

Info

Publication number
MX2018009820A
MX2018009820A MX2018009820A MX2018009820A MX2018009820A MX 2018009820 A MX2018009820 A MX 2018009820A MX 2018009820 A MX2018009820 A MX 2018009820A MX 2018009820 A MX2018009820 A MX 2018009820A MX 2018009820 A MX2018009820 A MX 2018009820A
Authority
MX
Mexico
Prior art keywords
cart19
cells
induce tolerance
deplete normal
present
Prior art date
Application number
MX2018009820A
Other languages
English (en)
Inventor
Carl H June
Bruce L Levine
Michael D Kalos
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2018009820A publication Critical patent/MX2018009820A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona composiciones y métodos para inducir tolerancia en un humano. La presente invención incluye administrar una célula T genéticamente modificada que expresa un CAR, en donde el CAR comprende un dominio de enlace de antígeno, un dominio de transmembrana, una región de señalización coestimuladora, y un dominio de señalización zeta CD3.
MX2018009820A 2012-07-13 2015-01-09 Uso de cart19 para eliminar celulas b normales para inducir tolerancia. MX2018009820A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261671508P 2012-07-13 2012-07-13

Publications (1)

Publication Number Publication Date
MX2018009820A true MX2018009820A (es) 2022-08-24

Family

ID=49916701

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015000433A MX382772B (es) 2012-07-13 2013-07-12 Composición para usarse para prevenir o retardar el rechazo de trasplante de un tejido u órgano trasplantado en un sujeto.
MX2018009820A MX2018009820A (es) 2012-07-13 2015-01-09 Uso de cart19 para eliminar celulas b normales para inducir tolerancia.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015000433A MX382772B (es) 2012-07-13 2013-07-12 Composición para usarse para prevenir o retardar el rechazo de trasplante de un tejido u órgano trasplantado en un sujeto.

Country Status (13)

Country Link
US (3) US20150290244A1 (es)
EP (1) EP2872184B1 (es)
JP (5) JP2015523386A (es)
KR (1) KR102216083B1 (es)
CN (2) CN104884095A (es)
AU (3) AU2013289984B2 (es)
BR (1) BR112015000657B1 (es)
CA (1) CA2876734A1 (es)
EA (2) EA034644B1 (es)
ES (1) ES2835232T3 (es)
IN (1) IN2015DN00139A (es)
MX (2) MX382772B (es)
WO (1) WO2014012001A2 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
EA034644B1 (ru) * 2012-07-13 2020-03-02 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Применение cart19 для истощения нормальных b-клеток для индукции толерантности
WO2014130657A1 (en) 2013-02-20 2014-08-28 The Trustees Of The University Of Pennsylvania Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
TW201446794A (zh) 2013-02-20 2014-12-16 Novartis Ag 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
SG11201604815RA (en) 2013-12-19 2016-07-28 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
EP4303229A3 (en) 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
SG11201606909RA (en) * 2014-04-07 2016-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
KR20220136455A (ko) 2014-04-23 2022-10-07 주노 쎄러퓨티크스 인코퍼레이티드 입양 치료용 면역 세포 집단의 단리, 배양 및 유전자 조작 방법
SG10201913782UA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
US10174095B2 (en) 2014-07-21 2019-01-08 Novartis Ag Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016028896A1 (en) 2014-08-19 2016-02-25 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
WO2016028879A1 (en) * 2014-08-19 2016-02-25 The Children's Hospital Of Philadelphia Compositions and methods for modulating immune response
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
AU2015317608B2 (en) 2014-09-17 2021-03-11 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
IL279420B2 (en) 2014-10-08 2024-09-01 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
KR102805767B1 (ko) 2014-12-29 2025-05-14 노파르티스 아게 키메라 항원 수용체-발현 세포를 제조하는 방법
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
AU2016245958B2 (en) 2015-04-08 2021-09-09 Novartis Ag CD20 therapies, CD22 therapies, and combination therapies with a CD19 Chimeric Antigen Receptor (CAR) - expressing cell
CN118726268A (zh) 2015-04-17 2024-10-01 诺华股份有限公司 改善嵌合抗原受体表达细胞的功效和扩增的方法
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CA2984975A1 (en) 2015-05-06 2016-11-10 Snipr Technologies Limited Altering microbial populations & modifying microbiota
TWI859112B (zh) 2015-07-21 2024-10-21 瑞士商諾華公司 改良免疫細胞之功效及擴展之方法
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
JP6905163B2 (ja) 2015-09-03 2021-07-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア サイトカイン放出症候群を予測するバイオマーカー
EP3858388B1 (en) * 2015-09-28 2024-07-03 Regents of the University of Minnesota Chimeric antigen receptor (car) t cells as therapeutic interventions for gvhd
CA3001910A1 (en) * 2015-10-13 2017-04-20 Eureka Therapeutics, Inc. Antibody agents specific for human cd19 and uses thereof
AU2016362129A1 (en) 2015-12-04 2018-06-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
US11413340B2 (en) 2015-12-22 2022-08-16 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
CA3020599A1 (en) * 2016-04-15 2017-10-19 The Children's Hospital Of Philadelphia Compositions and methods of chimeric alloantigen receptor t cells
MX2018012615A (es) * 2016-04-15 2019-05-30 Novartis Ag Composiciones y metodos para la expresion selectiva de proteinas.
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
BR112019001327A2 (pt) * 2016-07-29 2019-04-30 Juno Therapeutics Inc anticorpos anti-idiotípicos e métodos relacionados
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
CN110234327A (zh) * 2016-11-30 2019-09-13 英特拉克森公司 类固醇施用和免疫疗法
EP3346001A1 (en) * 2017-01-06 2018-07-11 TXCell Monospecific regulatory t cell population with cytotoxicity for b cells
WO2018140725A1 (en) 2017-01-26 2018-08-02 Novartis Ag Cd28 compositions and methods for chimeric antigen receptor therapy
SG11201907434RA (en) 2017-03-22 2019-10-30 Novartis Ag Compositions and methods for immunooncology
WO2019079569A1 (en) 2017-10-18 2019-04-25 Novartis Ag COMPOSITIONS AND METHODS FOR SELECTIVE DEGRADATION OF A PROTEIN
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
CN112203725A (zh) 2018-06-13 2021-01-08 诺华股份有限公司 Bcma嵌合抗原受体及其用途
AU2019311077B2 (en) * 2018-07-23 2025-05-29 Heidelberg Pharma Research Gmbh Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
CN113474450A (zh) 2018-08-09 2021-10-01 朱诺治疗学股份有限公司 产生工程化细胞的方法以及所述工程化细胞的组合物
CN112930399A (zh) 2018-08-31 2021-06-08 耶鲁大学 用于增强基于供体寡核苷酸的基因编辑的组合物和方法
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
CA3149421A1 (en) 2019-08-30 2021-03-04 Yale University Compositions and methods for delivery of nucleic acids to cells
AU2020393912B2 (en) 2019-11-26 2025-11-20 Novartis Ag Chimeric antigen receptors binding BCMA and CD19 and uses thereof
CA3162892A1 (en) 2019-11-26 2021-06-03 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
CN119842626A (zh) * 2019-12-27 2025-04-18 昭泰英基生物医药（香港）有限公司 一种工程化免疫杀伤细胞、其制备方法及应用
KR20220125310A (ko) * 2020-01-10 2022-09-14 코이뮨, 인크. 종양 치료 방법
JP2023544970A (ja) 2020-08-31 2023-10-26 イエール ユニバーシティ 細胞への核酸の送達のための組成物及び方法
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN120897933A (zh) 2022-10-11 2025-11-04 耶鲁大学 使用细胞穿透性抗体的组合物和方法
EP4626477A1 (en) 2022-12-01 2025-10-08 Yale University Stimuli-responsive traceless engineering platform for intracellular payload delivery
EP4574838A1 (en) 2023-12-21 2025-06-25 Vilnius University Chimeric antigen receptor (car) with enhanced recruitment of signaling partners

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200704871B (en) * 2004-11-17 2008-09-25 Angiogen Pharmaceuticals Pty L A method of modulating B cell functioning
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
EP1795588A1 (en) * 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
MX2011009312A (es) * 2009-03-06 2012-02-29 Medimmune Llc Formulaciones de anticuerpos humanizados anti-cd19.
US9181527B2 (en) * 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
JP5894538B2 (ja) * 2010-02-04 2016-03-30 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 炎症性ヒトＴｈ１７細胞の増殖および機能を決定的に調節するＩＣＯＳ
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2651442B1 (en) * 2010-12-14 2020-04-22 University of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
EA034644B1 (ru) * 2012-07-13 2020-03-02 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Применение cart19 для истощения нормальных b-клеток для индукции толерантности

Also Published As

Publication number Publication date
CN104884095A (zh) 2015-09-02
AU2018203756B2 (en) 2019-10-24
US20150290244A1 (en) 2015-10-15
KR20150030750A (ko) 2015-03-20
JP2020158541A (ja) 2020-10-01
BR112015000657A8 (pt) 2018-01-16
BR112015000657B1 (pt) 2023-12-05
BR112015000657A2 (pt) 2017-06-27
EP2872184A2 (en) 2015-05-20
JP2018135363A (ja) 2018-08-30
EP2872184B1 (en) 2020-09-16
CA2876734A1 (en) 2014-01-16
MX2015000433A (es) 2016-04-28
WO2014012001A3 (en) 2015-04-23
EA201992742A3 (ru) 2020-12-30
AU2020200315B2 (en) 2021-11-04
IN2015DN00139A (es) 2015-06-12
AU2020200315A1 (en) 2020-02-06
EA201992742A2 (ru) 2020-09-30
US20240261328A1 (en) 2024-08-08
EP2872184A4 (en) 2016-03-30
EA034644B1 (ru) 2020-03-02
ES2835232T3 (es) 2021-06-22
US20180271907A1 (en) 2018-09-27
JP2022173331A (ja) 2022-11-18
AU2013289984A1 (en) 2015-01-22
AU2013289984B2 (en) 2018-03-08
KR102216083B1 (ko) 2021-02-17
EA201590209A1 (ru) 2015-08-31
WO2014012001A2 (en) 2014-01-16
AU2018203756A1 (en) 2018-06-21
JP2025129358A (ja) 2025-09-04
JP2015523386A (ja) 2015-08-13
MX382772B (es) 2025-03-11
CN120393001A (zh) 2025-08-01

Similar Documents

Publication Publication Date Title
MX2018009820A (es) Uso de cart19 para eliminar celulas b normales para inducir tolerancia.
NI201300051A (es) Uso de células t de receptor modificado antígeno quiméricas para tratar el cáncer.
IN2014DN07414A (es)
MX2017003645A (es) Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
MX2013012593A (es) Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
MX2015000438A (es) Manejo de toxicidad para actividad antitumoral de cars.
MX2014010183A (es) Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer.
UY35468A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
MX2020001450A (es) Composiciones para reducir la inmunosupresion por celulas de tumor.
BR112013006718A2 (pt) epítopos de células t e receptores de células t antígeno-específicos
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
MX390943B (es) Receptores de antígeno quimérico cd33 y usos de los mismos.
UY34456A (es) Anticuerpos anti-il-36r
MX2016008076A (es) Receptores quimericos de antigeno de mesotelina humana y uso de los mismos.
NI201400061A (es) Anticuerpos anti - phf - tau y sus usos
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
TR201818988T4 (tr) Multipl skleroz semptomlarını hafifletmeye yönelik apoaequorin içeren bileşimlere dayalı yöntemler.
CU20130079A7 (es) Uso de células t modificadas por receptor de antígeno quimérico para tratar cáncer
TR201907505T4 (tr) Anti-DR5 ailesi antikorları, bispesifik veya çok değerlikli anti-DR5 ailesi antikorları ve bunların kullanım yöntemleri.